Sheehan G J, Harding G K, Haase D A, Thomson M J, Urias B, Kennedy J K, Hoban D J, Ronald A R
Department of Medicine, University of Manitoba, Winnipeg, Canada.
Antimicrob Agents Chemother. 1988 Aug;32(8):1292-3. doi: 10.1128/AAC.32.8.1292.
We evaluated the benefits of prolonging norfloxacin therapy from 12 to 24 weeks for complicated urinary tract infection in a double-blind, randomized, placebo-controlled study. During the second 12 weeks, norfloxacin was superior to placebo (P less than 0.05) in suppressing bacteriuria. Adverse effects were common but mostly confined to the initial 12 weeks.
在一项双盲、随机、安慰剂对照研究中,我们评估了将诺氟沙星治疗复杂尿路感染的疗程从12周延长至24周的益处。在第二个12周期间,诺氟沙星在抑制菌尿方面优于安慰剂(P<0.05)。不良反应常见,但大多局限于最初的12周。